Pazopanib and Liposomal Doxorubicin in the Treatment of Patients with Relapsed/Refractory Epithelial Ovarian Cancer: A Phase Ib Study of the Sarah Cannon Research Institute. (16th March 2015)

• Record Type: Journal Article
• Authors: Hainsworth, John D.; Firdaus, Irfan D.; Earwood, Chris B.; Chua, Cynthia C.
• Is Part Of: Cancer investigation. Volume 33:Number 3(2015)
• Page Start: 47
• Page End: 52
• Publication Date: 2015-03-16
• Subjects: Ovarian cancer -- Angiogenesis -- Chemotherapy; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.3109/07357907.2014.998833
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract : Purpose : To investigate the combination of liposomal doxorubicin/pazopanib in advanced relapsed/refractory ovarian cancer. Patients and Methods : Twenty-two patients received liposomal doxorubicin/pazopanib. Initial doses (liposomal doxorubicin, 40 mg/m 2 monthly; pazopanib, 400 mg daily) were too toxic; three subsequent groups received lower doses/altered schedules. Results : The maximum tolerated doses (MTD) were liposomal doxorubicin, 30 mg/m 2, and pazopanib, 400 mg daily. Severe toxicity included neutropenia (18%), rash/desquamation (14%), hypertension (9%), and hand–foot syndrome (9%). Five of the eight patients treated with MTD had grade 3 toxicity during the first two cycles. Dose reductions were frequently required. Conclusions : Further development of the liposomal doxorubicin/pazopanib combination is not recommended.